Study of Platelet Population Changes Under Circulatory Support With ECMO
Condition(s) studied
Study summary
Advances in flow cytometry techniques have led to a better understanding of platelet phenotypes and have revealed the existence of four major platelet populations with distinct functional properties (native, proaggregating, procoagulating, or apoptotic). These phenotypes have a significant impact on the hemostatic capacity of blood platelets, and a proportional change in these populations during ECMO treatment could, at least in part, contribute to the observed complications.
Eligibility
Primary outcome measure(s)
- Proportional Changes in the Different Platelet Populations (native, proaggregating, procoagulant, or apoptotic) — Days 1, 3, and 7 after the initiation of ECMO treatment.
Proportional Changes in the Different Platelet Populations (native, proaggregating, procoagulant, or apoptotic) on Days 1, 3, and 7 after the initiation of ECMO treatment.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Service d'anesthésie-réanimation - CHU de Strasbourg - France | Strasbourg | France | Recruiting |
More University Hospital, Strasbourg, France trials in France
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07334457 on ClinicalTrials.gov ↗ ← All trials in France